Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Johnson & Johnson to $166 from $163 and keeps an Equal Weight rating on the shares. The company’s 2024 sales growth outlook implies Q4 growth deceleration, but the management’s commentary regarding 2025 is encouraging for EPS growth, the analyst tells investors in a research note. J&J also believes that “meaningful progress” has been made in resolving the talc litigation, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Bridgeport jury determines J&J to pay $15M over talc-based powder
- Johnson & Johnson price target raised to $170 from $160 at Stifel
- Legend Biotech weakness a buying opportunity, says Barclays
- Big banks, UnitedHealth report quarterly earnings: Morning Buzz
- Unusually active option classes on open October 15th